

Style	Date	Time	Session	Presentation No.	Abstract No.	First Name	Last Name	Country	Title
Oral	13-May	8:28-8:35	Systemic Chemotherapy & Oncology 1	O22-05	10131	Sadahisa	Ogasawara	Japan	Sorafenib and Regorafenib Sequential Therapies in Japanese Patients with Advanced Hepatocellular Carcinoma-Initial Experience from Single Institution
Oral	13-May	8:35-8:42	Systemic Chemotherapy & Oncology 1	O22-06	10165	Tamami	Abe	Japan	Serial Changes in Liver Function Parameters during Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma
Oral	13-May	8:42-8:49	Systemic Chemotherapy & Oncology 1	O22-07	10207	Yoshiyuki	Wada	Japan	Regorafenib as Second-Line Treatment of Patients with Hepatocellular Carcinoma (HCC) who Progressed on Sorafenib: Subgroup Analysis of Patients from Asia in the Phase 3 RESORCE Trial
Oral	13-May	8:49-8:56	Systemic Chemotherapy & Oncology 2	O23-01	10212	Hirosvohi	Taniuchi	Japan	Argon Plasma Laser Coagulation is Effective for Gastrointestinal Bleeding from Radiation Gastritis Exacerbated by Sorafenib
Oral	13-May	8:56-9:03	Systemic Chemotherapy & Oncology 2	O23-02	10286	Masaru	Enomoto	Japan	Changes in Plasma IL-8 and TNF- α Levels during the Early Treatment Period as a Predictor of the Response to Sorafenib in Patients with Unresectable HCC
Oral	13-May	9:03-9:10	Systemic Chemotherapy & Oncology 2	O23-03	10301	Chikara	Ogawa	Japan	Hand-Foot Syndrome as a Predictor of Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib
Oral	13-May	9:10-9:17	Systemic Chemotherapy & Oncology 2	O23-04	10315	Kyo	Sasaki	Japan	Treatment of Hepatocellular Carcinoma using 2-deoxy-D-glucose Encapsulated in PLGA Nanoparticles in Mice
Oral	13-May	9:17-9:24	Systemic Chemotherapy & Oncology 2	O23-05	10318	Hisanori	Muto	Japan	Complete Response of Advanced Hepatocellular Carcinoma Achieved with Sorafenib Dose Re-Escalation
Oral	13-May	9:24-9:31	Systemic Chemotherapy & Oncology 2	O23-06	10319	Taku	Tanaka	Japan	A Case of Advanced Hepatocellular Carcinoma Achieving Long Term Stable Disease(SD) after Discontinuation of Sorafenib
Oral	13-May	9:31-9:38	Systemic Chemotherapy & Oncology 2	O23-07	10334	Satoru	Abe	Japan	The Effect of C-Met Inhibitor on Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis
Oral	13-May	9:38-9:45	TACE, HAIC & Vascular Interventions 1	O24-01	10075	Kenichiro	Kodama	Japan	Comparison of Clinical Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib for Advanced Hepatocellular Carcinoma According to Macrovascular Invasion and TACE Refractory
Oral	13-May	9:45-9:52	TACE, HAIC & Vascular Interventions 1	O24-02	10119	Mohamed	Kohla	Egypt	Can Hepatoma Arterial Embolization (HAP) Score Predict Survival in Egyptian Patients with Hepatocellular Carcinoma Treated by TACE?
Oral	13-May	9:52-9:59	TACE, HAIC & Vascular Interventions 1	O24-03	10146	Takashi	Niizeki	Japan	Robust Efficacy of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Comparative Study with Sorafenib
Oral	13-May	10:00-10:07	TACE, HAIC & Vascular Interventions 1	O24-04	10173	Ming	Liu	China	Quantitative Perfusion Analysis of Hepatocellular Carcinoma Treated with Transarterial Arterial Chemoembolization by Contrast Enhanced Ultrasound
Oral	13-May	10:07-10:14	TACE, HAIC & Vascular Interventions 1	O24-05	10174	Ming	Liu	China	Hepatocellular Carcinoma Treated with Transarterial Arterial Chemoembolization: Influence Factors of Local Efficacy Analyzed by Parametric Contrast Enhanced Ultrasound
Oral	13-May	10:14-10:21	TACE, HAIC & Vascular Interventions 2	O25-01	10258	Ashish	Kumar	India	Combination of Sorafenib with Transarterial Chemoembolization (TACE) Improves Survival as Compared to TACE Alone in Patients with Hepatocellular Carcinoma: A Metaanalysis of 18 Studies
Oral	13-May	10:21-10:28	TACE, HAIC & Vascular Interventions 2	O25-02	10267	Masatoshi	Tanaka	Japan	A Role of Intra-arterial Chemotherapy as a Part of Multidisciplinary Treatment for Advanced HCC
Oral	13-May	10:28-10:35	TACE, HAIC & Vascular Interventions 2	O25-03	10310	Pil Soo	Sung	Korea	Complete Pathological Response after Transarterial Chemoembolization for HCC Predicts Outcomes after Liver Resection or Transplantation
Oral	13-May	10:35-10:42	TACE, HAIC & Vascular Interventions 2	O25-04	10340	Shiro	Miyayama	Japan	Efficacy of Automated Tumor-Feeder Detection Software in Conventional Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma
Oral	13-May	10:42-10:49	TACE, HAIC & Vascular Interventions 2	O25-05	10409	Xi-Zhang	Lin	Taiwan	Preliminary Safety and Efficacy Evaluation of a New Iodized Oil for Transarterial Chemoembolization.
Oral	13-May	10:49-10:56	TACE, HAIC & Vascular Interventions 3	O26-01	10410	Yen-Cheng	Chiu	Taiwan	Using T-ACE Beads for Embolization Therapy of Hepatocellular Carcinoma: First-in-human Study.
Oral	13-May	10:56-11:03	TACE, HAIC & Vascular Interventions 3	O26-02	10422	Jose Gillan E.	Cataluna	Philippines	Incidence and Risk Factors of Acute Kidney Injury after Transarterial Chemoembolization among Patients with Hepatocellular Carcinoma in a Large Tertiary Hospital: A Single-Center Retrospective Cohort Study
Oral	13-May	11:03-11:10	TACE, HAIC & Vascular Interventions 3	O26-03	10468	Ulfa	Kholili	Indonesia	Predictives Factors of Alfa Feto Protein Decreasing After First Transarterial Chemoembolization Procedures in Hepatocellular Carcinoma Patients
Oral	13-May	11:10-11:17	TACE, HAIC & Vascular Interventions 3	O26-04	10471	Umami	Maimunah	Indonesia	The Clinical Features and Alfa Feto Protein Decreasing in Different Size Lesion among Hepatocellular Carcinoma who Underwent First TACE
Oral	13-May	11:17-11:24	TACE, HAIC & Vascular Interventions 3	O26-05	10474	Peremba Bodi	Setiawan	Indonesia	Predictive Factors of Tumor Size Reduction After First TACE Procedures in Hepatocellular Carcinoma Patient